EPO to Award Alnylam Patent on Use of RNAi Molecules in Cancer

The intellectual property, EP Application No 02702247.4, is derived from the so-called Kreutzer-Limmer III patent series developed by Germany’s Ribopharma, which Alnylam acquired in 2003 and later sold off to Roche.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories